

# Canaan

## Len Post

Executive in Residence / East Coast  
Since 2016

Len Post joined Canaan with over 30 years of experience in all stages of pharmaceutical and biotechnology company R&D, from early drug discovery through clinical development and FDA approval. He has extensive experience in oncology and genetic diseases. He currently serves as Chief Scientific Officer and Director of Vivace Therapeutics. Prior to joining Canaan, he was a founder of US-based LEAD Therapeutics in 2007 which was subsequently acquired by BioMarin Pharmaceuticals in 2010. Len served as the Chief Scientific Officer of BioMarin Pharmaceuticals until 2016.

Len was Senior Vice President of R&D at Onyx Pharmaceuticals and was responsible for the co-development (50:50 with Bayer) of Nexavar (sorafenib), from IND through FDA approval for renal cell carcinoma.

Previously, as VP of Discovery Research at Parke-Davis, he led a multi-national drug discovery organization of over 800 people, in cancer, infectious diseases, inflammation, cardiovascular and CNS. He has also held several positions at the Upjohn Company, including Director of Infectious Disease Research. During his industry career, he has led numerous programs that have resulted in multiple clinical candidates across various therapeutic areas.

Len received a B.S. in Chemistry from the University of Michigan and a Ph.D. in Biochemistry from the University of Wisconsin, Madison after which he performed a Postdoctoral Fellowship in Virology at the University of Chicago.

## About Canaan

Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With \$5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan's focus areas include fintech, enterprise/cloud, marketplaces, frontier tech, biopharma, digital health and medtech. To learn more about our people and our portfolio, please visit [canaan.com](http://canaan.com).